Neuropeptide Growth Factors

References

• Chang M M, Leeman S E. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterisation as substance P. J Biol Chem 1970; 245: 4784–4790
   PubMed Web of Science ®Google Scholar
• Mudge A W. Developmental neurobiology. Neuropeptides find a role?. Nature 1989; 339: 663
   PubMed Web of Science ®Google Scholar
• Zachary I, Woll P J, Rozengurt E. A role for neuropeptides in the control of cell proliferation. Devel Biol 1987; 124: 295–308
   PubMed Web of Science ®Google Scholar
• Andrews P C, Brayton K, Dixon J E. Precursors to regulatory peptides: their proteolytic processing. Experientia 1987; 43: 784–790
   PubMedGoogle Scholar
• Polak J M, Bloom S R. Regulatory peptides. Experientia 1987; 43: 723–850
   PubMedGoogle Scholar
• Hokfelt T, Milhorn D, Seroogy K, et al. Coexistence of peptides with classical neurotransmitters. Experientia 1987; 43: 768–790
   PubMedGoogle Scholar
• Anastasi A, Erspamer V, Bucci M. Isolation and structure of bombesin and alytensin, two analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 1971; 27: 166–167
   PubMedGoogle Scholar
• McDonald T J, Jornvall H, Nilsson G, et al. Characterisation of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem Biophys Res Commun 1979; 90: 227–233
   PubMed Web of Science ®Google Scholar
• Roth K A, Evans C J, Lorenz R G, et al. Identification of gastrin-releasing peptide related substances in guinea pig and rat brain. Biochem Biophys Res Commun 1983; 112: 528–536
   PubMed Web of Science ®Google Scholar
• Panula P. Histochemistry and function of bombesin-like peptides. Med Biol 1986; 64: 177
   PubMedGoogle Scholar
• Price J, Penman E, Bourne G L, et al. Characterisation of bombesin-like immunoreactivity in human fetal lung. Reg Pept 1983; 7: 315–322
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Abe K, Kameya T, et al. Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumours. Cancer Res 1983; 43: 3932–3939
   PubMed Web of Science ®Google Scholar
• Lebacq-Verheyden A-M, Bertness V, Kirsch, et al. Human gastrin-releasing peptide gene maps to chromosome brand 18q21. Somatic Cell Mol Genet 1987; 13: 81–86
   PubMedGoogle Scholar
• Naylor S L, Sakaguchi A Y, Spindel E, et al. Human gastrin-releasing peptide gene is located on chromosome 18. Somatic Cell Mol Genet 1987; 13: 87–91
   PubMedGoogle Scholar
• Brown M, Rivier J, Vale W. Bombesin: potent effects on thermoregulation in the rat. Science 1977; 196: 998–1000
   PubMed Web of Science ®Google Scholar
• Brown M, Rivier J, Vale W. Bombesin affects the central nervous system to produce hyperglycemia in rats. Life Sci 1977; 21: 1729–1734
   PubMed Web of Science ®Google Scholar
• Spindel E. Mammalian bombesin-like peptides. TINS 1986; 130–133
   Web of Science ®Google Scholar
• Wharton J, Polak J M, Bloom S R, et al. Bombesin-like immunoreactivity in the lung. Nature 1978; 273: 769–770
   PubMed Web of Science ®Google Scholar
• Spindel E R, Sunday M E, Hofler H, et al. Transient elevation of messenger RNA encoding gastrin-releasing peptide, a putative pulmonary growth factor in human fetal lung. J Clin Invest 1987; 80: 1172–1179
   PubMed Web of Science ®Google Scholar
• Willey J C, Lechner J F, Harris C C. Bombesin and the C-terminal tetradecapeptide of gastrin-releasing peptide are growth factors for normal human bronchial epithelial cells. Exp Cell Res 1984; 153: 245–248
   PubMed Web of Science ®Google Scholar
• Moody T W, Pert C B, Gazdar A F, et al. Highlevels of intracellular bombesin characterize human small-cell lung carcinoma. Science 1981; 214: 1246–1248
   PubMed Web of Science ®Google Scholar
• Carney D N, Gazdar A F, Bepler G, et al. Establishment and characterisation of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985; 45: 2913–2923
   PubMed Web of Science ®Google Scholar
• Sausville E A, Lebacq-Verheyden A-M, Spindel E R, et al. Expression of the gastrin-releasing peptide gene in human small cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs. J Biol Chem 1986; 261: 2451–2457
   PubMed Web of Science ®Google Scholar
• Cuttitta F, Fedorko J, Gu J, et al. Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer: a novel peptide family found in man. J Clin Endocrin Metab 1988; 67: 576–583
   PubMed Web of Science ®Google Scholar
• Maruno K, Yamaguchi K, Abe K, et al. Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1989; 49: 629–632
   PubMed Web of Science ®Google Scholar
• Moody T W, Bertness V, Carney D N. Bombesin-like peptides and receptors in human tumor cell lines. Peptides 1983; 4: 683–686
   PubMed Web of Science ®Google Scholar
• Weber S, Zuckerman J E, Bostwick D G, et al. Gastrin-releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. J Clin Invest 1985; 75: 306–309
   PubMed Web of Science ®Google Scholar
• Carney D N, Cuttitta F, Moody T W, et al. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res 1987; 47: 821–825
   PubMed Web of Science ®Google Scholar
• Layton J E, Scanlon D B, Soveny C, et al. Effects of bombesin antagonists on the growth of small cell lung cancer in vitro. Cancer Res 1988; 48: 4783–4789
   PubMed Web of Science ®Google Scholar
• Kado-Fong H, Malfroy B. Effects of bombesin on human small cell lung cancer cells: evidence for a subset of bombesin non-responsive cell lines. J Cell Biochem 1989; 40: 431–437
   PubMed Web of Science ®Google Scholar
• Alexander R W, Upp J R, Poston G J, et al. Effects of bombesin on growth of human small cell lung carcinoma in vivo. Cancer Res 1988; 48: 1439–1441
   PubMed Web of Science ®Google Scholar
• Aguayo S M, Kane M A, King T E, et al. Increased levels of bombesin-like peptides in the lower respiratory tract of asymptomatic cigarette smokers. J Clin Invest 1989; 84: 1105–1113
   PubMed Web of Science ®Google Scholar
• Bologna M, Festuccia C, Muzi P, et al. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989; 63: 1714–1720
   PubMed Web of Science ®Google Scholar
• Boden G, Shelmet J J. Gastrointestinal hormones and carcinoid tumours and syndrome. Endocrinology and Metabolism 2nd Ed, P Felig, J D Baxter, A E Broadus, L A Frohman. McGraw-Hill, New York 1987; 1629–1662
   Google Scholar
• Goodlad R A, Wright N A. Peptides and epithelial growth regulation. Experientia 1987; 43: 780–784
   PubMedGoogle Scholar
• Staley J, Fiskum G, Moody T W. Cholecystokinin elevates cytosolic calcium in small cell lung cancer cells. Biochem Biophys Res Commun 1989; 163: 605–610
   PubMed Web of Science ®Google Scholar
• Woll P J, Rozengurt E. Multiple neuropeptides mobilise calcium in small cell lung cancer: effects of vasopressin, bradykinin, cholecystokinin, galanin and neurotensin. Biochem Biophys Res Commun 1989; 164: 66–73
   PubMed Web of Science ®Google Scholar
• Cooper J R, Bloom F E, Roth R H. The Biochemical Basis of Neuropharmacology, 5th Ed. Oxford University Press, New York 1986
   Google Scholar
• Wharton J, Gulbenkian. Peptides in the mammalian cardiovascular system. Experientia 1987; 43: 821–850
   PubMedGoogle Scholar
• Hultgardh-Nilsson A, Nilsson J, Jonzon B, et al. Growth inhibitory properties of vasoactive intestinal polypeptide. Regul Pept 1988; 20: 267–274
   Google Scholar
• Nilsson J, Von Euler A M, Dalsqaard C J. Stimulation of connective tissue cell growth by substance P and substance K. Nature 1985; 315: 61–63
   PubMed Web of Science ®Google Scholar
• Dalsgaard C-J, Haultgardh-Nilsson A, Haegerstrand A, et al. Neuropeptides as growth factors. Possible roles in human diseases. Regul Peptides 1989; 25: 1–9
   PubMed Web of Science ®Google Scholar
• Friesen S R. Tumors of the endocrine pancreas. N Engl J Med 1982; 306: 580–590
   PubMed Web of Science ®Google Scholar
• Miller R P, Husain F, Svensson M, et al. Enhancement of [3H-methyljthymidine incorporation and replication of rat chondrocytes grown in tissue culture by plasma, tissue extracts and vasopressin. Endocrinology 1977; 100: 1365–1375
   PubMed Web of Science ®Google Scholar
• Rozengurt E, Legg A, Pettican P. Vasopressin stimulation of mouse 3T3 cell growth. Proc Natl Acad Sci (USA) 1979; 76: 1284–1287
   PubMed Web of Science ®Google Scholar
• Russell W E, Bucher N LR. Vasopressin modulates liver regeneration in the Brattleboro rat. Am J Physiol 1983; 245: G321–G324
   PubMed Web of Science ®Google Scholar
• Boer G J. Vasopressin and brain development: studies using the Brattleboro rat. Peptides 1985; 6(suppl 1)49–62
   PubMedGoogle Scholar
• Solcia E, Usellini L, Buffa R, et al. Endocrine cells producing regulatory peptides. Experientia 1987; 43: 839–847
   PubMedGoogle Scholar
• Odell W D. Paraendocrine syndromes of cancer. Adv Intern Med 1989; 34: 325–353
   PubMedGoogle Scholar
• Crosby S R, Stewart M F, Ratcliffe J G, et al. Direct measurement of the precursors of adrenocorticotrophin in human plasma by two-site immunoradiometric assay. J Clin Endocrinol Metabol 1988; 67: 1272–1277
   PubMed Web of Science ®Google Scholar
• Roth K A, Barchas J D. Small cell carcinoma cell lines contain opioid peptides and receptors. Cancer 1986; 57: 769–773
   PubMed Web of Science ®Google Scholar
• Davis T P, Burgess H S, Crowell S, et al. β-Endorphin and neurotensin stimulate in vitro clonal growth of human SCLC cells. Eur J Pharmacol 1989; 161: 283–285
   PubMed Web of Science ®Google Scholar
• Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77–79
   PubMed Web of Science ®Google Scholar
• Moreau J P, DeFeudis F V. Pharmacological studies of somatostatin and somatostatin-analogues: therapeutic advances and perspectives. Life Sci 1987; 40: 419–437
   PubMed Web of Science ®Google Scholar
• Frohman L A, Kreiger D T. Neuroendocrine physiology and disease. Endocrinology and Metabolism, 2nd ed., P Felig, J D Baxter, A E Broadus, L A Frohman. McGraw-Hill, New York 1987; 185–247
   Google Scholar
• Bloom S R, Polak J M. Somatostatin. Br Med J 1987; 295: 288–290
   PubMed Web of Science ®Google Scholar
• Iversen L L. Nonopioid neuropeptides in mammalian CNS. Annu Rev Pharmacol Toxicol 1983; 23: 1–27
   PubMed Web of Science ®Google Scholar
• Case Records of Massachusetts General Hospital. N Engl J Med 1989; 320: 996–1004
   PubMed Web of Science ®Google Scholar
• Reubi J C, Maurer R, Von Werder J, et al. Somatostatin receptors in human endocrine tumors. Cancer Res 1987; 47: 551–558
   PubMed Web of Science ®Google Scholar
• Reubi J C, Landolt A M. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 1984; 59: 1148–1151
   PubMed Web of Science ®Google Scholar
• Reubi J C, Rivier J, Perrin M, et al. Specific high affinity binding sites for somatostatin-28 on pancreatic β-cells: differences with brain somatostatin receptors. Endocrinology 1982; 110: 1049–1051
   PubMed Web of Science ®Google Scholar
• Reubi J C, Waser B, Sheppard M, Macaulay V M. Somatostatin receptors are present in small cell but not in non-small cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer 1990; 45: 269–274
   PubMed Web of Science ®Google Scholar
• Yanaihara N, Kobayashi S, Sato H, et al. Vasoactive intestinal polypeptide-like immunoreactivity in a human neuroblastoma cell line and the coexistence of other neuropeptide immunoreactivity in the cell line. Endocrinol Jpn 1980; 1(suppl)37–42
   Google Scholar
• Long R G, Polak J M, Bloom S R. Hormones and the gastrointestinal tract. Oxford Textbook of Medicine, D J Weatherall, J GG Ledingham, D A Warrell. Oxford University Press, Oxford 1983; 12.47–12.57
   Google Scholar
• Maciewicz R, Martin J B. Pain, pathophysiology and management. Harrison's Principles of Internal Medicine 11th ed., E Braun-Wald, K J Isselbacher, T G Petersdorf, J D Wilson, J B Martin, A S Fauci. McGraw-Hill, New York 1987; 13–17
   Google Scholar
• Payan D G, Brewster D R, Goetzl E J. Specific stimulation of human T lymphocytes by substance P. J Immunol 1983; 131: 1613–1615
   PubMed Web of Science ®Google Scholar
• Lotz M, Carson D A, Vaughan J H. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987; 235: 893–895
   PubMed Web of Science ®Google Scholar
• Lazarus L H, DiAugustine R P, Jahnke G D, et al. Physalaemin: an amphibian tachykinin in human small cell carcinoma. Science 1983; 219: 79–81
   PubMed Web of Science ®Google Scholar
• Bepler G, Carney D N, Gazdar A F, et al. In vitro growth inhibition of human small cell lung cancer by physalaemin. Cancer Res 1987; 47: 2371–2375
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415
   PubMed Web of Science ®Google Scholar
• Black P N, Ghatei M A, Takahashi K, et al. Formation of endothelin by cultured airway epithelial cells. FEBS Lett 1989; 255: 129–132
   PubMed Web of Science ®Google Scholar
• Yoshizawa T, Shinmi O, Giaid A, et al. Endothelin: a novel peptide in the posterior pituitary system. Science 1990; 247: 462–464
   PubMed Web of Science ®Google Scholar
• Fabregat I, Rozengurt E. Vasoactive intestinal contractor, a novel peptide, shares a common receptor with endothelin-1 and stimulates Ca2+ mobilization and DNA synthesis in Swiss 3T3 cells. Biochem Biophys Res Commun 1990; 167: 161–167
   PubMed Web of Science ®Google Scholar
• Hanley M R. Peptide regulatory factors in the nervous system. Lancet 1989; i: 1373–1376
   Google Scholar
• Woll P J, Rozengurt E. Two classes of antagonist interact with receptors for the mitogenic neuropeptides bombesin, bradykinin and vasopressin. Growth Factors 1988; 1: 75–83
   PubMedGoogle Scholar
• Blackburn A M, Fletcher D R, Adrian T E, et al. Neurotensin infusion in man: pharmacokinetics and effect on gastrointestinal and pituitary hormones. J Clin Endocrinol Metabol 1980; 51: 1257–1261
   PubMed Web of Science ®Google Scholar
• Goedert M, Reeve J G, Emson P C, et al. Neurotensin in human small cell lung carcinoma. Br J Cancer 1984; 50: 179–183
   Google Scholar
• Hanley M R, Jackson T R. Substance K receptor: the return of the magnificent seven. Nature 1987; 329: 766–767
   PubMed Web of Science ®Google Scholar
• Michell R H. Peptide regulatory factors. Post-receptor signalling pathways. Lancet 1989; 1: 765–768
   PubMed Web of Science ®Google Scholar
• Guadino G, Cirillo D, Naldini L, et al. Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell carcinomas. Proc Natl Acad Sci (USA) 1988; 85: 2166–2170
   PubMed Web of Science ®Google Scholar
• Gomperts B D. Involvement of guanine nucleoude-binding protein in the gating of Ca2+ by receptors. Nature 1983; 306: 64–66
   PubMed Web of Science ®Google Scholar
• Jackson T R, Blair L AC, Marshall J, et al. The mas oncogene encodes an angiotensin receptor. Nature 1988; 335: 437–439
   PubMed Web of Science ®Google Scholar
• Ross E M, Gilman A G. Biochemical properties of hormone sensitive adenylate cyclase. Ann Rev Biochem 1980; 49: 533–564
   PubMed Web of Science ®Google Scholar
• Rozengurt E. Early signals in the mitogenic response. Science 1986; 234: 161–166
   PubMed Web of Science ®Google Scholar
• Rozengurt E, Mendoza S A. Synergistic signals in mitogenesis: role of ion fluxes, cyclic nucleotides and protein kinase C in Swiss 3T3 cells. J Cell Sci 1985; 3(suppl)229–242
   Google Scholar
• Heikkila R, Trepel J B, Cuttitta F, et al. Bombesin-related peptides induce calcium mobilisation in a subset of human SCLC cell lines. J Biol Chem 1987; 262: 16456–16460
   PubMed Web of Science ®Google Scholar
• Moody T W, Murphy A, Mahmoud S, et al. Bombesin-like peptides elevate cytosolic calcium in SCLC cells. Biochem Biophys Res Commun 1987; 147: 189–195
   PubMed Web of Science ®Google Scholar
• Trepel J B, Moyer J D, Cuttitta F, et al. A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line. Biochem Biophys Res Commun 1988; 156: 1383–1389
   PubMed Web of Science ®Google Scholar
• Kishimoto A, Takai Y, Kikkawa U, et al. Activation of calcium and phospholipid-dependent protein kinase C by diacylglycerol, its possible relation to phosphatidylinositol turnover. J Biol Chem 1980; 255: 2273–2276
   PubMed Web of Science ®Google Scholar
• Vara F, Rozengurt E. Stimulation of Na+/H+ antiport activity by epidermal growth factor and insulin occurs without activation of protein kinase C. Biochem Biophys Res Commun 1985; 130: 646–653
   PubMed Web of Science ®Google Scholar
• Zachary I, Sinnett-Smith J W, Rozengurt E. Early events elicited by bombesin and structurally related peptides in quiescent Swiss 3T3 cells. I. Activation of protein kinase C and inhibition of epidermal growth factor binding. J Cell Biol 1986; 102: 2211
   PubMed Web of Science ®Google Scholar
• Erusalimsky J D, Friedberg I, Rozengurt E. Bobmesin diacylglycerols, and phorbol esters rapidly stimulate the phosphorylation of an Mr = 80,000 protein kinase C substrate in permeabilized 3T3 cells. Effects of guanine nucleotides. J Biol Chem 1988; 263: 19188–19194
   PubMed Web of Science ®Google Scholar
• Muller R, Bravo R, Burckhardt J, Curran T. Induction of c-fos gene and protein by growth factors precedes activation of c-myc. Nature 1984; 312: 716–720
   PubMed Web of Science ®Google Scholar
• Palumbo A P, Rossino P, Comoglio P M. Bombesin stimulation of c-fos and c-myc expression in cultures of Swiss 3T3 cells. Exp Cell Res 1986; 167: 276–280
   PubMed Web of Science ®Google Scholar
• Rozengurt E, Sinnett-Smith J W. Bombesin induction of c-fos and c-myc proto-oncogenes in Swiss 3T3 cells: significance for the mitogenic response. J Cell Physiol 1987; 131: 218–225
   PubMed Web of Science ®Google Scholar
• Bravo R, MacDonald-Bravo H, Muller R, et al. Bombesin induces c-fos and c-myc expression in quiescent Swiss 3T3 cells. Comparative study with other mitogens. Exp Cell Res 1987; 170: 103–115
   PubMed Web of Science ®Google Scholar
• Cuttitta F, Carney D N, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 1985; 316: 823–826
   PubMed Web of Science ®Google Scholar
• Mulshine J L, Avis I, Treston A M, et al. In vivo diagnosis and therapy of human tumors with monoclonal antibodies: selection of antibodies and preliminary clinical studies in small cell carcinoma of the lung. Nucl Med Biol 1989; 16: 159–162
   Web of Science ®Google Scholar
• Sikora K. Imaging with radiolabeled monoclonal antibodies. Clin Radiol 1989; 40: 332–334
   PubMed Web of Science ®Google Scholar
• Souhhami R L, Beverley P CL, Bobrow L. Proceedings of the first international workshop on small cell lung cancer antigens. Lung Cancer 1988; 4: 1–116
   Google Scholar
• Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for therapy. Nature 1988; 332: 323–327
   PubMed Web of Science ®Google Scholar
• Masui H, Kamrath H, Apell G, et al. Cytotoxicity against human tumor cells mediated by the conjugate of antiepidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res 1989; 49: 3482–34887
   PubMed Web of Science ®Google Scholar
• Bagshawe K. Towards generating cytotoxic agents at cancer sites. Br J Cancer 1989; 60: 275–281
   PubMed Web of Science ®Google Scholar
• Gullick W J. Inhibitors of growth factor receptors. 1990, In press
   Google Scholar
• Kull F C, Jacobs S, Ying-Fu S, et al. Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem 1983; 258: 6561–6566
   PubMed Web of Science ®Google Scholar
• Arteaga C L, Kitten L J, Coronado E B, et al. Blockade of the type 1 somatomedin receptor inhibits growth of human cancer cells in athymic mice. J Clin Invest 1984; 84: 1418–1423
   Google Scholar
• Nakanishi Y, Mulshine J L, Kaprzyk P G, et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 1988; 82: 354–359
   PubMed Web of Science ®Google Scholar
• Macaulay V M, Everard M J, Teale J D, et al. Autocrine function for insulin-like growth factor-I in human small cell lung cancer cell lines and fresh tumour cells. Cancer Res 1990; 50: 2511–2517
   PubMed Web of Science ®Google Scholar
• Mulshine J L. Therapeutic applications of growth factors. Lung Cancer 1988; 4(suppl)P29
   Google Scholar
• Schwartz J, Penke B, Rivier J, et al. A new cytotoxin specific for the target cells of corticotropin-releasing factor. Endocrinol 1987; 121: 1454–1460
   PubMed Web of Science ®Google Scholar
• Bacha P, Murphy J R, Reichlin S. Thyrotropin-releasing hormone-diphtheria toxin-related polypeptide conjugates. J Biol Chem 1983; 258: 1565–1570
   PubMed Web of Science ®Google Scholar
• Bajusz S, Janaky T, Csernus V J, et al. Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proc Nad Acad Sci (USA) 1989; 86: 6313–6317
   PubMed Web of Science ®Google Scholar
• Yaish P, Gazk A, Gilcon C, et al. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988; 242: 933–935
   PubMed Web of Science ®Google Scholar
• Sibley D R, Benovic J L, Caron M MG, et al. Regulation of transmembrane signalling by receptor phosphorylation. Cell 1987; 48: 913–922
   PubMed Web of Science ®Google Scholar
• Millar J B, Rozengurt E. Heterologous desensitization of bombesin-induced mitogenesis by prolonged exposure to vasopressin: a post-receptor signal transduction block. Proc Natl Acad Sci (USA) 1989; 86: 3204–3208
   PubMed Web of Science ®Google Scholar
• Johnson T C, Sharifi B G. Abrogation of the mitogenic activity of bombesin by a cell surface sialoglycopeptide growth inhibitor. Biochem Biophys Res Commun 1989; 161: 468–474
   PubMed Web of Science ®Google Scholar
• Matuoka K, Fukami K, Nakanishi O, et al. Mitogenesis in response to PDGF and bombesin abolished by micro-injection of antibody to PIP2. Science 1988; 239: 640–643
   PubMed Web of Science ®Google Scholar
• Mendoza S M, Schneider J A, Lopez-Rivas A, et al. Early events elicited by bombesin and structurally related peptides in quiescent Swiss 3T3 cells. JJ. Changes in Na+/ and Ca2+ fluxes, Na+/K+ pump activity, and intracellular pH. J Cell Biol 1986; 102: 2223–2233
   PubMed Web of Science ®Google Scholar
• Rosenblatt M. Seminars in medicine: peptide hormone antagonists that are effective in vivo. N Engl J Med 1986; 315: 1004–1013
   PubMed Web of Science ®Google Scholar
• Schally A V, Comaru-Schally A-M, Redding T W. Antitumour effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med 1984; 175: 259–281
   PubMed Web of Science ®Google Scholar
• Waxman J. Gonadotrophin hormone releasing analogoues open new doors in cancer treatment. Br Med J 1987; 295: 1084–1085
   PubMed Web of Science ®Google Scholar
• Schally A V. Oncological applications of somatostatin analogues. Cancer Res 1988; 48: 6977–6985
   PubMed Web of Science ®Google Scholar
• Smith C W, Walter R. Vasopressin analog with extraordinarily high antiduretic potency: a study of conformation and activity. Science 1978; 199: 297–299
   PubMed Web of Science ®Google Scholar
• Mukai H, Kawai K, Suzuki S, et al. [Ala6]gastrin-releasing peptide-10: an analogue with dissociated biological activities. Am J Physiol 1989; 257: 235–240
   Google Scholar
• Von Schrenck T, Heinz-Erian P, Moran R, , Gardner J D, Jensen R T, et al. Neuromedin B receptor in esophagus: evidence for subtypes of bombesin receptors. Am J Physiol 1989; 256: G747–G758
   PubMed Web of Science ®Google Scholar
• Martin W R. Pharmacology of opioids. Pharmacol Rev 1983; 35: 283–323
   PubMed Web of Science ®Google Scholar
• Sawyer W H, Manning M. The development of vasopressin antagonists. Fed Proc 1984; 43: 87–90
   PubMedGoogle Scholar
• Iversen L L (1985) Multiple receptors for tachykinins. Tachykinin Antagonists. Proceedings of the 8th Eric K Fernstrom Symposium, GlumslovSweden, June, 1985, R Hakanson, F Sundler. Elsevier, Amsterdam, 291–304
   Google Scholar
• Sternberg M JE, Gullick W J. Neu receptor dimerization. Nature 1989; 339: 587
   PubMed Web of Science ®Google Scholar
• Woll P J, Rozengurt E. Bombesin and bombesin antagonists: studies in Swiss 3T3 cells and human small cell lung cancer. Br J Cancer 1988; 57: 579–586
   PubMed Web of Science ®Google Scholar
• Jensen R T, Jones S W, Folkers K, et al. A synthetic peptide that is a bombesin receptor antagonist. Nature 1984; 309: 61–63
   PubMed Web of Science ®Google Scholar
• Yuachnis A T, Crawley J N, Jensen R T, et al. The antagonism of bombesin in the CNS by substance P analogues. Life Sci 1984; 35: 1963–1969
   PubMed Web of Science ®Google Scholar
• Post C, Butterworth J F, Strichartz G R, et al. Tachykinin antagonists have potent local anaesthetic actions. Eur J Pharmacol 1985; 17: 347–354
   Google Scholar
• Corps A N, Rees L H, Brown K D. A peptide that inhibits the mitogenic stimulation of Swiss 3T3 cells by bombesin or vasopressin. Biochem J 1985; 231: 781
   PubMed Web of Science ®Google Scholar
• Zachary I, Rozengurt E. A substance P antagonist also inhibits specific binding and mitogenic effects of vasopressin and bombesin-related peptides in Swiss 3T3 cells. Biochem Biophys Res Commun 1986; 137: 135
   PubMed Web of Science ®Google Scholar
• Woll P J, Rozengurt E. [D-Arg1, D-Phe5, D-Trp79 Leu11] substance P, a potent bombesin antagonists in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci (USA) 1988; 85: 1859–1863
   PubMed Web of Science ®Google Scholar
• Coy D H, Heinz-Erian P, Jiang N-Y, et al. Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity. J Biol Chem 1988; 263: 5056–5060
   PubMed Web of Science ®Google Scholar
• Dickinson K EJ, Uemura N, Sekar M C, et al. Partial agonist activity of the bombesin receptor antagonist [Leu14- (CH2/NH)Leu13] bombesin in frog peptic cells. Biochem Biophy Res Commun 1988; 157: 1154–1158
   PubMed Web of Science ®Google Scholar
• Woll P J, Coy D H, Rozengurt E. [Leu13- (CH2NH)Leu14] is a specific bombesin receptor antagonist in Swiss 3T3 cells. Biochem Biophys Res Commun 1988; 155: 359–365
   PubMed Web of Science ®Google Scholar
• Mahmoud S, Palaszynski E, Fiskum G, et al. Small cell lung cancer bombesin receptors are antagonized by reduced peptide bond analogues. Life Sci 1989; 44: 367–373
   PubMed Web of Science ®Google Scholar
• Rivier J, Brown M, Vale W. D-Trp-8-somatostatin: an analog of somatostatin more potent than the native molecule. Biochem Biophys Res Commun 1975; 65: 746–751
   PubMed Web of Science ®Google Scholar
• Veber D F, Freidinger R M, Schwenk-Perlow D, et al. A potent cyclic hexapeptide analogue of somatostatin. Nature (Lond) 1981; 292: 55–58
   PubMed Web of Science ®Google Scholar
• Bauer W, Briner U, Doepfner W, et al. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133–1140
   PubMed Web of Science ®Google Scholar
• Plewe G, Noelken G, Krause U, et al. Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201–995 in type I diabetes mellitus. Hormone Res 1987; 27: 7–12
   PubMed Web of Science ®Google Scholar
• Editorial. Octreotide. Lancet 1989; 2: 543–544
   PubMedGoogle Scholar
• Mascardo R N, Sherline P. Somatostatin inhibits rapid centrasomal separation and cell proliferation induced by epidermal growth factor. Endocrinology 1982; 111: 1394–1396
   PubMed Web of Science ®Google Scholar
• Hierowski M T, Liebow C, Du Sapin K, et al. Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett 1985; 179: 252–256
   PubMed Web of Science ®Google Scholar
• Plewe G, Beyer J, Krause U, et al. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201–995 in acromegaly. Lancet 1984; 2: 782–784
   PubMed Web of Science ®Google Scholar
• Lamberts S WJ, Uitterlinden P, Verschoor L, et al. Long term treatment of acromegaly with the somatostatin analog SMS 201–995. N Engl J Med 1985; 313: 1576–1580
   PubMed Web of Science ®Google Scholar
• Lamberts S WJ, Uitterlinden, Del Pozo E. SMS 201–995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of aromegalic patients for over two years. J Clin Endocrinol Metabol 1987; 65: 703–710
   PubMed Web of Science ®Google Scholar
• Comi R J. Pharmacology and use in pituitary tumors, pp 36–451. Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestingal tract and non-neoplastic diseases of the gut (Gorden P, moderator). Ann Intern Med 1989; 110: 35–50
   PubMed Web of Science ®Google Scholar
• Kvols L K, Moertel C G, O'Connell M J, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663–666
   PubMed Web of Science ®Google Scholar
• Ellison E C, O'Dorisio T M, Benson G D. Modulation of functional gastrointestinal endocrine tumors by endogeneous and exogeneous somatostatin. Am J Med 1986; 151: 668–675
   Google Scholar
• Boden G, Ryan I G, Eisenschmid B L, et al. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201–995. N Engl J Med 1986; 314: 1686–1689
   PubMed Web of Science ®Google Scholar
• Ellison E C, Grower W R, Elkhammas E, et al. Characterisation of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201–995). Am J Med 1986; 81: 56–64
   PubMed Web of Science ®Google Scholar
• Wood S M, Kraenslin M E, Adrian T E, et al. Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue; symptomatic and peptide responses. Gut 1985; 26: 438–444
   PubMed Web of Science ®Google Scholar
• Kraenzlin M E, Ch'ng J C, Wood S M, et al. Long term treatment of a VTPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88: 185–1287
   PubMed Web of Science ®Google Scholar
• Maton P N. Use in patients with gut neuroendocrine tumours, pp 41–44. In Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic disease of the gut (Gorden P, moderator). Ann Intern Med 1989; 110: 35–50
   PubMed Web of Science ®Google Scholar
• Krenning E P, Breeman W AP, Koorj P PM, et al. Localisation of endocrine-related tumours with radioiodonated analogue of somatostatin. Lancet 1989; 1: 242–244
   PubMed Web of Science ®Google Scholar
• Reubi J C, Horisberger U, Essed C E, et al. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 1988; 95: 760–763
   PubMed Web of Science ®Google Scholar
• Liebow C, Hierowski M, Du Sapin K. Hormonal control of pancreatic cancer growth. Pancreas 1986; 1: 44–48
   PubMedGoogle Scholar
• Liebow C, Reilly C, Serrano M, et al. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci 1989; 86: 2003–2007
   PubMed Web of Science ®Google Scholar
• Szende B, Zalatnai A, Schally A V. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci (USA) 1989; 86: 1643–1647
   PubMed Web of Science ®Google Scholar
• Viguerie N, Tahiri-Jouti N, Ayral A M, et al. Direct inhibitory effects of a somatostatin analog, SMS 201–995, on ARA-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism. Endocrinology 1989; 124: 1017–1025
   PubMed Web of Science ®Google Scholar
• Upp J R, Olson D, Poston G J, et al. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201–995. J Am Surg 1988; 155: 29–35
   Google Scholar
• Setyono-Han B, Henkelman M S, Foekens J A, et al. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 1987; 47: 1566–1570
   PubMed Web of Science ®Google Scholar
• Fekete M, Redding T W, Comaru-Schally A M, et al. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate 1989; 14: 191–208
   PubMed Web of Science ®Google Scholar
• Weber C, Merriam L, Koschitzky T, et al. Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201–995: treatment of nude mouse xenografts. Surgery 1989; 106: 416–422
   PubMed Web of Science ®Google Scholar
• Vennnin P H, Peyrat J P, Bonneterre J, et al. Effect of the long-acting somatostatin analogue SMS 201–995 (Sandostatin) in advanced breast cancer. Anticancer Res 1989; 9: 153–156
   PubMed Web of Science ®Google Scholar
• Taylor J E, Coy D H, Moreau J-P. High affinity binding of [125I-Tyr11]Somatostatin-14 to human small cell hing carcinoma (NCI-H69). Life Sci 1988; 43: 421–427
   PubMed Web of Science ®Google Scholar
• Taylor J E, Bogden A E, Moreau J P, et al. In vitro and in vivo inhibition of human small cell lung cancer (NCI-H69) growth by a somatostatin analog. Biochem Biophys Res Commun 1988; 153: 81–86
   PubMed Web of Science ®Google Scholar
• Macaulay V M, Smith I E, Everard M J, et al. Experimental and clinical studies with octreotide (SMS 201–995, Sandostatin) in small cell lung cancer. 1990, In preparation
   Google Scholar
• Schally A V, Redding T W. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci (USA) 1987; 84: 7275–7279
   PubMed Web of Science ®Google Scholar
• Salomon D S, Paglia L M, Verbruggen L. Hormone-dependent growth of a rat chondrosarcoma in vivo. Cancer Res 1979; 39: 4387–4395
   PubMed Web of Science ®Google Scholar
• McCumbee W D, McCarty K S, Jr, Lebovitz H E. Hormone responsiveness of a transplantable rat chondrosarcoma U. Evidence for in vivo hormone dependence. Endocrinology 1980; 105: 1930–1940
   Google Scholar
• Redding T W, Schally A V. Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones. Proc Natl Acad Sci (USA) 1983; 80: 1078–1182
   PubMed Web of Science ®Google Scholar
• Reubi J C. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol 1985; 109: 108–114
   PubMedGoogle Scholar
• Palmer-Smith J, Solomon T E. Effects of gastrin, proglumide and somatostatin on growth of human colon cancer. Gastroenterology 1988; 95: 1541–1548
   PubMed Web of Science ®Google Scholar